



Invited perspective

Therapeutic potential of chemokine signal inhibition for metastatic breast cancer

Takanori Kitamura^a, Jeffrey W. Pollard^{a,b,*}^a MRC Centre for Reproductive Health, The Queen's Medical Research Institute, The University of Edinburgh, 47 Little France Crescent, Edinburgh EH16 4TJ, UK^b Department of Developmental and Molecular Biology, Albert Einstein College of Medicine, 1300 Morris Park Avenue, Bronx, NY 10543, USA

ARTICLE INFO

Article history:

Received 6 August 2015

Accepted 7 August 2015

Available online 11 August 2015

Keywords:

Breast cancer

Metastasis

Macrophage

Chemokine

ABSTRACT

Metastatic breast cancer is incurable by current therapies including chemotherapy and immunotherapy. Accumulating evidence indicates that tumor-infiltrating macrophages promote establishment of the lethal metastatic foci and contribute to therapeutic resistance. Recent studies suggest that the accumulation of these macrophages is regulated by a chemokine network established in the tumor microenvironment. In this perspective paper, we elaborate on the chemokine signals that can attract monocytes/macrophages to the site of metastasis, and discuss whether inhibition of these chemokine signals can represent a new therapeutic strategy for metastatic breast cancer.

© 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license (<http://creativecommons.org/licenses/by/4.0/>).

1. Introduction

Breast cancer is a leading cause of cancer death in women largely due to metastasis that develop in the bone and lung. The 5-year survival of patients with metastatic disease drops to 21% whereas that of patients with early-stage breast cancer is 89–100% [1]. It has been reported that 6–10% of breast cancer patients are found to have metastasis at initial diagnosis and ~30% of tumor-resected patients develop distant metastases [2], indicating the failure of current therapies and requirement of novel strategies to prevent tumor growth at the metastatic sites. Among potential new therapeutic targets are stromal cells, especially macrophages, within the tumor microenvironment as they promote establishment of the lethal metastatic tumors [3–6] and prevent the efficacy of current therapies [7–9].

In breast cancer mouse models, lung metastatic foci show marked accumulation of a distinct macrophage population (F4/80⁺CD11b⁺Ly6C[−]) that is barely found in the normal lung [10]. In an experimental model of pulmonary metastasis, these

metastasis-associated macrophages (MAMs) are recruited to the lung and directly contact with disseminating mammary tumor cells within 24–48 h post-tumor injection, which enhances extravasation of the circulating tumor cells and suppresses tumor cell apoptosis [10,11]. Since genetic depletion of these CD11b⁺ macrophages reduces the metastatic tumor burden in the lung [10], blockade of the MAM accumulation is an attractive therapeutic strategy for metastatic breast cancer.

It has been reported that the recruitment of macrophages to the primary site is promoted by various cytokines and chemokines such as colony stimulating factor-1 (CSF-1), vascular endothelial growth factor (VEGF) and CC-chemokine ligand 2 (CCL2), although the mechanisms underlying macrophage accumulation in the metastasis sites are still largely unknown. We have recently reported that the accumulation of MAMs at the metastatic lung is regulated by chemokine ligands CCL2 and CCL3 and their respective receptors CCR2 and CCR1 [12,13]. In this perspective paper, we describe the roles of these chemokine signals in the MAM accumulation, and discuss therapeutic potential of their blockade for metastatic breast cancer.

2. Accumulation of metastasis-associated macrophages via chemokine signals

It has been reported that high levels of CCL2 in breast cancer specimens correlate with high number of macrophages in the primary tumors [14], suggesting pivotal roles of CCL2 in macrophage recruitment to the tumor microenvironment. We recently demon-

Abbreviations: MAM, metastasis-associated macrophages; CSF-1, colony stimulating factor-1; VEGF, vascular endothelial growth factor; CCL, CC-chemokine ligand; CCR, CC-chemokine receptor; IM, inflammatory monocyte; CXCL, CXC-chemokine ligand; CXCR, CXC-chemokine receptor.

* Corresponding author at: MRC Centre for Reproductive Health, The Queen's Medical Research Institute, The University of Edinburgh, 47 Little France Crescent, Edinburgh, EH16 4TJ, UK.

E-mail address: jeff.pollard@ed.ac.uk (J.W. Pollard).

<http://dx.doi.org/10.1016/j.phrs.2015.08.004>

1043-6618/© 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license (<http://creativecommons.org/licenses/by/4.0/>).




Fig. 1. Model for a chemokine cascade that promotes metastatic seeding of cancer cells. Cancer or host cell derived CCL2 promotes recruitment of inflammatory monocytes (IMs) from circulation to the metastasis sites. These recruited IMs differentiate into metastasis-associated macrophages (MAMs) that express higher levels of CCR1. In the MAMs, CCL2-CCR2 signaling increases expression of CCL3. CCL3-CCR1 autocrine signaling enhances and stabilizes cancer cell-MAM interaction in part through integrin $\alpha 4$ binding to VCAM1 expressed on the tumor cell [11]. This results in the retention of MAMs that further promotes metastatic seeding of cancer cells through at least in part conferring survival signals on the metastatic cell. Blue and red arrows show CCL2 and CCL3 mediated events respectively. Dotted lines indicate secretion of chemokines.

strated that anti-CCL2 antibody treatment decreases the number of MAMs at the metastatic sites and reduces metastatic tumor burden in an experimental model of breast cancer lung metastasis [12]. In this model, anti-CCL2 antibody treatment also inhibited the migration of adoptively transferred inflammatory monocytes (IMs; CD11b⁺Ly6C^{high}) to the tumor challenged lung. These results indicate that the CCL2-CCR2 signal recruits circulating IMs to the site of metastasis where they differentiate into MAMs and promote establishment of metastatic foci. We have further found that the MAMs isolated from the mouse lung with metastatic foci express much higher level of CCL3 compared with circulating IMs [13]. Interestingly, the CCL3 expression in MAMs is significantly suppressed by anti-CCL2 antibody treatment, suggesting that MAMs secrete high level of CCL3 once they differentiate from IMs and this is partly through activation of the CCL2-CCR2 signaling pathway. Genetic loss of host CCL3 or its receptor CCR1 reduces the MAM accumulation in the tumor-challenged lung 24 h after tumor injection and decreases number of metastatic foci. Loss of CCR1 also prevents MAM-cancer cell interactions and following retention of MAMs in the tumor-challenged lung. These findings collectively indicate that activation of the CCL3-CCR1 axis in MAMs via CCL2 signaling promotes retention of MAMs and subsequent metastatic seeding of breast cancer cells (Fig. 1). These results suggest that distinct chemokine receptors regulate specific process of the monocyte/macrophage accumulation, i.e., recruitment by CCL2-CCR2 and retention by CCL3-CCR1 axis. Consistent with this suggestion, in vitro studies show that migration, adhesion, and differentiation of human monocytes are promoted by CCL2, CXCL18, and CXCL12 respectively [15–17].

In our breast cancer model, another CCL3 receptor CCR5 is not necessary for the early MAM accumulation observed within 24 h after tumor injection. However, it is reported that CCR5 is required for macrophage accumulation in the lung foci after 7 days of renal cancer cell injection [18], suggesting that macrophages use different chemokine receptors to accumulate in the distinct microenvironments at different phases of metastasis. Recent studies utilizing the PyMT mice suggest that a chemokine receptor predominantly used for macrophage accumulation might be skewed by the induction of a specific ligand in the tumor microenvironment. Namely, increased CCL2 level in the tumor by doxorubicin treatment promotes CCR2 dependent monocyte recruitment [19], although the PyMT mammary tumors normally recruit monocytes/macrophages via CCR6 but not CCR2 [20,21]. Induction of

certain ligands in cancer cells as they progress may also determine the chemokine receptor required for the macrophage accumulation since the primary tumors developed by mouse breast cancer cells that overexpress CXCL12 or CX3CL1 recruit macrophages through CXCR4 or CX3CR1 respectively [22,23]. In the primary tumors developed by 4T1 mouse breast cancer cells, inhibition of either CCR2 or CXCR2 can reduce the number of macrophages [24,25], which also suggests the involvement of multiple chemokine signals in the macrophage accumulation in the tumor microenvironment. However, most of these findings come from in vitro systems or primary tumor models. Further studies are required to evaluate the involvements of these chemokine signals other than CCL2 and CCL3 in the MAM accumulation at the metastasis sites, as their actions might represent therapeutic targets for metastatic diseases.

3. Inhibition of chemokine signals to prevent metastatic outgrowth of breast cancer cells

The ultimate objective of macrophage-targeting therapy is withdrawal of tumor-supporting and immunosuppressive microenvironment from the secondary sites by disrupting accumulation and/or function of MAMs. Accordingly, the above-mentioned chemokine signaling molecules are potential targets for the treatment of metastatic breast cancer.

Results from our breast cancer metastasis model suggest that the inhibition of CCL3 secretion from MAMs is one of the possible strategies as they are a major source of CCL3 among other leukocytes such as neutrophils, T, B, and NK cells in the metastatic lung [13]. CCL2 is another possible target fitting this strategy since CCL2 neutralizing antibody can suppress *Ccl3* expression in MAMs as well as their recruitment following mammary tumor metastasis [12,13]. However, humanized monoclonal CCL2 neutralizing antibody (CNT0888) is ineffective in suppressing serum CCL2 level or tumor progression due to feedback mechanism that increases CCL2 production [26]. Furthermore, discontinuing anti-CCL2 treatment is reported to cause rebound influx of monocytes into the metastatic sites that enhances metastatic outgrowth [24]. These reports suggest difficulty in suppressing MAM accumulation by CCL2 deprivation, and indicates requirement for another target. In our model, the anti-CCL2 antibody treatment reduces CCL3 expression in MAMs but inhibition rate is only 40% compared with IgG treatment [13], suggesting that factors other than CCL2 from cancer cells and/or tumor microenvironment also involve in CCL3 secretion from MAMs. It has been reported that CCL3 expression in bone marrow-derived macrophages is increased by granulocyte-macrophage colony-stimulating factor (GM-CSF), IL-3 and IL-33 [27,28]. Interestingly, chemokine ligands such as CCL5 and CCL18 can also promote secretion of various chemokines including CCL3 from cultured human monocytes [29,30]. These cytokines and chemokines could be alternative targets to suppress CCL3 secretion, although further studies are required to understand their expression in metastatic sites and their contribution to MAM accumulation.

Another possible strategy to suppress MAM accumulation is blockade of CCR1 and CCR2. Several companies have developed small molecule inhibitors against CCR1 or CCR2 for rheumatoid arthritis or multiple sclerosis, and most of them are well tolerated and show no adverse effects [31]. These antagonists were developed for autoimmune diseases, and thus clinical trials for cancer are very limited. Nevertheless, an anti-CCR2 antibody (MLN1202) tested in a phase II clinical trial for metastatic cancer showed therapeutic effects in 14 out of 43 patients with bone metastases (ClinicalTrials.gov ID: NCT01015560). Most recently, Chemocentryx initiated a phase Ib trial of their next-generation CCR2 antagonist (CCX872) for non-resectable pancreatic cancer

Download English Version:

<https://daneshyari.com/en/article/5843343>

Download Persian Version:

<https://daneshyari.com/article/5843343>

[Daneshyari.com](https://daneshyari.com)